Skip to content

Inspection Record

Isologic Innovative Radiopharmaceuticals of Ontario Limited — Health Canada Inspection Findings

Health CanadaInspected 2026-08-25 6 findingsAseptic processing and sterility assuranceOther quality systemEquipment and facilityLaboratory and QC controlsDeviation, CAPA, and investigation

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

The condition of the clean area used to produce sterile products was inadequate.

2Other quality system

The traceability, legibility, documentation, formatting, and/or the accuracy of records was inadequate.

3Equipment and facility

Evaluation of production processes, equipment, and/or materials was inadequate.

4Laboratory and QC controls

The quality control department did not undertake all of the required activities.

5Deviation, CAPA, and investigation

The evaluation was inadequate for cases where there was a deviation from the norm and/or where products were on the borderline of the acceptable range. Investigations into deviations, reports, and/or follow-up actions were inadequate.

6Deviation, CAPA, and investigation

The establishment and/or the maintenance of a data governance plan was inadequate. The company's investigations of microbial contamination in critical areas were inadequate.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the Health Canada inspection on 2026-08-25. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Isologic Innovative Radiopharmaceuticals of Ontario Limited findings history — including this company's other documentsAll Health Canada findings Health Canada documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.